Non-serious adverse events
|
Cohort 0: LEE011 200mg 21 on/7 off + TMT212 2 mg QD |
Cohort 1: TMT212 1.5 mg QD + LEE011 200 mg QD - Schedule 1 |
Cohort 2a: TMT212 2 mg QD + LEE011 200 mg QD- Schedule 1 |
Cohort 2b: TMT212 1.5 mg QD + LEE011 300 mg QD- Schedule 1 |
Cohort 3a: TMT212 2 mg QD + LEE011 300 mg QD- Schedule 1 |
Cohort 3b: TMT212 1.5 mg QD + LEE011 400 mg QD - Schedule 1 |
Cohort 4a: TMT212 2 mg QD + LEE011 400 mg QD - Schedule 1 |
Cohort 4a*: TMT212 2 mg QD + LEE011 400 mg QD- Schedule 2 |
Cohort 5a: TMT212 2 mg QD + LEE011 500 mg QD- Schedule 1 |
Cohort Xa: TMT212 1 mg QD + LEE011 300 mg QD- Schedule 1 |
Cohort Xb: TMT212 1 mg QD + LEE011 400 mg QD- Schedule 1 |
All Subjects |
Total subjects affected by non serious adverse events
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
5 / 5 (100.00%) |
7 / 7 (100.00%) |
6 / 6 (100.00%) |
5 / 5 (100.00%) |
12 / 12 (100.00%) |
12 / 12 (100.00%) |
10 / 10 (100.00%) |
8 / 9 (88.89%) |
10 / 10 (100.00%) |
10 / 10 (100.00%) |
9 / 9 (100.00%) |
94 / 95 (98.95%) |
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
|
|
|
|
|
|
|
|
|
|
|
|
|
Pyogenic granuloma
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Tumour pain
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
1 / 5 (20.00%) |
0 / 12 (0.00%) |
2 / 12 (16.67%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
4 / 95 (4.21%) |
occurrences all number
|
0 |
0 |
1 |
1 |
0 |
2 |
0 |
0 |
0 |
0 |
0 |
4 |
Vascular disorders
|
|
|
|
|
|
|
|
|
|
|
|
|
Deep vein thrombosis
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Embolism
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
Hypertension
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
2 / 7 (28.57%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
3 / 10 (30.00%) |
0 / 9 (0.00%) |
2 / 10 (20.00%) |
1 / 10 (10.00%) |
1 / 9 (11.11%) |
11 / 95 (11.58%) |
occurrences all number
|
1 |
2 |
0 |
0 |
2 |
0 |
3 |
0 |
2 |
1 |
1 |
12 |
Hypotension
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
3 / 95 (3.16%) |
occurrences all number
|
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
0 |
0 |
3 |
Lymphoedema
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
2 |
Vascular rupture
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
General disorders and administration site conditions
|
|
|
|
|
|
|
|
|
|
|
|
|
Chills
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
2 / 7 (28.57%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
1 / 12 (8.33%) |
1 / 10 (10.00%) |
1 / 9 (11.11%) |
1 / 10 (10.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
8 / 95 (8.42%) |
occurrences all number
|
0 |
2 |
0 |
0 |
1 |
1 |
1 |
3 |
1 |
1 |
0 |
10 |
Device related thrombosis
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Face oedema
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Fatigue
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 5 (60.00%) |
5 / 7 (71.43%) |
3 / 6 (50.00%) |
4 / 5 (80.00%) |
8 / 12 (66.67%) |
7 / 12 (58.33%) |
6 / 10 (60.00%) |
4 / 9 (44.44%) |
5 / 10 (50.00%) |
5 / 10 (50.00%) |
4 / 9 (44.44%) |
54 / 95 (56.84%) |
occurrences all number
|
3 |
5 |
3 |
4 |
9 |
7 |
7 |
5 |
6 |
5 |
4 |
58 |
Gait disturbance
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
Influenza like illness
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Malaise
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
1 |
Non-cardiac chest pain
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
0 |
0 |
3 |
Oedema
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Oedema peripheral
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
2 / 6 (33.33%) |
1 / 5 (20.00%) |
5 / 12 (41.67%) |
5 / 12 (41.67%) |
5 / 10 (50.00%) |
3 / 9 (33.33%) |
1 / 10 (10.00%) |
1 / 10 (10.00%) |
2 / 9 (22.22%) |
26 / 95 (27.37%) |
occurrences all number
|
0 |
1 |
4 |
1 |
7 |
6 |
6 |
3 |
1 |
1 |
2 |
32 |
Pain
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Peripheral swelling
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
0 |
0 |
2 |
Pyrexia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
3 / 7 (42.86%) |
1 / 6 (16.67%) |
1 / 5 (20.00%) |
4 / 12 (33.33%) |
3 / 12 (25.00%) |
2 / 10 (20.00%) |
3 / 9 (33.33%) |
3 / 10 (30.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
22 / 95 (23.16%) |
occurrences all number
|
1 |
5 |
1 |
1 |
4 |
3 |
2 |
3 |
3 |
1 |
0 |
24 |
Secretion discharge
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
1 / 5 (20.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Suprapubic pain
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
Swelling face
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
Temperature intolerance
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Xerosis
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
2 |
Immune system disorders
|
|
|
|
|
|
|
|
|
|
|
|
|
Contrast media reaction
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
Immune system disorder
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Seasonal allergy
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Reproductive system and breast disorders
|
|
|
|
|
|
|
|
|
|
|
|
|
Benign prostatic hyperplasia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Breast pain
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Pelvic pain
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Scrotal pain
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
1 / 5 (20.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Uterine pain
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Vulvovaginal pruritus
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
Respiratory, thoracic and mediastinal disorders
|
|
|
|
|
|
|
|
|
|
|
|
|
Aphonia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Cough
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
1 / 7 (14.29%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
2 / 9 (22.22%) |
8 / 95 (8.42%) |
occurrences all number
|
1 |
1 |
1 |
0 |
1 |
1 |
0 |
2 |
0 |
0 |
2 |
9 |
Dysphonia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
4 / 95 (4.21%) |
occurrences all number
|
0 |
1 |
0 |
0 |
1 |
0 |
1 |
1 |
0 |
0 |
0 |
4 |
Dyspnoea
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
2 / 6 (33.33%) |
1 / 5 (20.00%) |
3 / 12 (25.00%) |
1 / 12 (8.33%) |
2 / 10 (20.00%) |
2 / 9 (22.22%) |
1 / 10 (10.00%) |
1 / 10 (10.00%) |
2 / 9 (22.22%) |
16 / 95 (16.84%) |
occurrences all number
|
0 |
1 |
2 |
1 |
3 |
1 |
2 |
2 |
1 |
1 |
2 |
16 |
Dyspnoea at rest
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Dyspnoea exertional
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
Epistaxis
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
4 / 95 (4.21%) |
occurrences all number
|
1 |
1 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
0 |
0 |
4 |
Haemoptysis
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
2 |
Increased upper airway secretion
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Nasal congestion
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
Oropharyngeal pain
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
2 / 12 (16.67%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
3 / 95 (3.16%) |
occurrences all number
|
0 |
0 |
0 |
0 |
2 |
0 |
0 |
1 |
0 |
0 |
0 |
3 |
Pharyngeal inflammation
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Pleural effusion
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
1 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
2 |
Pleuritic pain
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
Pneumonitis
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
Productive cough
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
3 / 95 (3.16%) |
occurrences all number
|
1 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
0 |
3 |
Rhinorrhoea
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 10 (20.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
0 |
0 |
2 |
Sleep apnoea syndrome
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Psychiatric disorders
|
|
|
|
|
|
|
|
|
|
|
|
|
Anxiety
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
1 |
0 |
1 |
0 |
0 |
0 |
2 |
Bruxism
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Confusional state
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
2 |
Depression
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
3 / 95 (3.16%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
0 |
0 |
3 |
Insomnia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
2 |
Mental status changes
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
Sleep disorder
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Investigations
|
|
|
|
|
|
|
|
|
|
|
|
|
Activated partial thromboplastin time prolonged
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
2 |
Alanine aminotransferase increased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
0 / 7 (0.00%) |
2 / 6 (33.33%) |
2 / 5 (40.00%) |
2 / 12 (16.67%) |
2 / 12 (16.67%) |
2 / 10 (20.00%) |
4 / 9 (44.44%) |
2 / 10 (20.00%) |
0 / 10 (0.00%) |
2 / 9 (22.22%) |
19 / 95 (20.00%) |
occurrences all number
|
2 |
0 |
3 |
3 |
2 |
3 |
2 |
12 |
3 |
0 |
2 |
32 |
Amylase increased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
1 / 10 (10.00%) |
1 / 10 (10.00%) |
2 / 9 (22.22%) |
7 / 95 (7.37%) |
occurrences all number
|
0 |
0 |
2 |
0 |
0 |
1 |
0 |
3 |
2 |
1 |
4 |
13 |
Aspartate aminotransferase increased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
1 / 7 (14.29%) |
4 / 6 (66.67%) |
4 / 5 (80.00%) |
5 / 12 (41.67%) |
4 / 12 (33.33%) |
7 / 10 (70.00%) |
5 / 9 (55.56%) |
4 / 10 (40.00%) |
1 / 10 (10.00%) |
2 / 9 (22.22%) |
38 / 95 (40.00%) |
occurrences all number
|
2 |
2 |
5 |
5 |
6 |
4 |
8 |
8 |
6 |
1 |
2 |
49 |
Bilirubin conjugated increased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
1 |
Blood alkaline phosphatase increased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
3 / 7 (42.86%) |
2 / 6 (33.33%) |
2 / 5 (40.00%) |
2 / 12 (16.67%) |
1 / 12 (8.33%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
2 / 10 (20.00%) |
0 / 10 (0.00%) |
2 / 9 (22.22%) |
15 / 95 (15.79%) |
occurrences all number
|
0 |
3 |
2 |
2 |
4 |
1 |
1 |
0 |
3 |
0 |
4 |
20 |
Blood bilirubin increased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
2 / 10 (20.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
6 / 95 (6.32%) |
occurrences all number
|
1 |
0 |
1 |
0 |
0 |
1 |
3 |
0 |
0 |
1 |
0 |
7 |
Blood creatine increased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
0 |
0 |
2 |
Blood creatine phosphokinase increased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 5 (40.00%) |
3 / 7 (42.86%) |
3 / 6 (50.00%) |
1 / 5 (20.00%) |
6 / 12 (50.00%) |
6 / 12 (50.00%) |
4 / 10 (40.00%) |
4 / 9 (44.44%) |
5 / 10 (50.00%) |
0 / 10 (0.00%) |
3 / 9 (33.33%) |
37 / 95 (38.95%) |
occurrences all number
|
2 |
3 |
4 |
1 |
10 |
6 |
6 |
8 |
7 |
0 |
3 |
50 |
Blood creatinine decreased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Blood creatinine increased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
3 / 6 (50.00%) |
0 / 5 (0.00%) |
2 / 12 (16.67%) |
2 / 12 (16.67%) |
0 / 10 (0.00%) |
2 / 9 (22.22%) |
1 / 10 (10.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
11 / 95 (11.58%) |
occurrences all number
|
0 |
0 |
3 |
0 |
2 |
3 |
0 |
3 |
3 |
2 |
0 |
16 |
Blood urea increased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
C-reactive protein increased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Ejection fraction decreased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
4 / 95 (4.21%) |
occurrences all number
|
1 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
0 |
4 |
Electrocardiogram QT prolonged
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
Gamma-glutamyltransferase increased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
1 / 7 (14.29%) |
1 / 6 (16.67%) |
1 / 5 (20.00%) |
1 / 12 (8.33%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
8 / 95 (8.42%) |
occurrences all number
|
1 |
1 |
2 |
1 |
1 |
1 |
0 |
1 |
0 |
0 |
1 |
9 |
International normalised ratio increased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
Lipase increased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
1 / 12 (8.33%) |
1 / 10 (10.00%) |
1 / 9 (11.11%) |
2 / 10 (20.00%) |
0 / 10 (0.00%) |
2 / 9 (22.22%) |
9 / 95 (9.47%) |
occurrences all number
|
0 |
0 |
1 |
0 |
1 |
1 |
1 |
6 |
3 |
0 |
4 |
17 |
Liver function test increased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
Lymphocyte count decreased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
2 / 7 (28.57%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
4 / 95 (4.21%) |
occurrences all number
|
0 |
2 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
4 |
Monocyte count decreased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
1 |
Neutrophil count decreased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
4 / 12 (33.33%) |
0 / 12 (0.00%) |
2 / 10 (20.00%) |
1 / 9 (11.11%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
10 / 95 (10.53%) |
occurrences all number
|
0 |
0 |
2 |
0 |
6 |
0 |
3 |
1 |
1 |
0 |
2 |
15 |
Neutrophil count increased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Platelet count decreased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 5 (40.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
2 / 12 (16.67%) |
1 / 10 (10.00%) |
1 / 9 (11.11%) |
2 / 10 (20.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
10 / 95 (10.53%) |
occurrences all number
|
2 |
0 |
0 |
0 |
2 |
2 |
1 |
1 |
2 |
1 |
0 |
11 |
Weight decreased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
1 / 10 (10.00%) |
2 / 9 (22.22%) |
7 / 95 (7.37%) |
occurrences all number
|
0 |
1 |
0 |
0 |
1 |
0 |
1 |
1 |
0 |
1 |
2 |
7 |
Weight increased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
White blood cell count decreased
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
3 / 12 (25.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
3 / 10 (30.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
9 / 95 (9.47%) |
occurrences all number
|
0 |
2 |
0 |
0 |
0 |
4 |
0 |
2 |
4 |
0 |
1 |
13 |
Injury, poisoning and procedural complications
|
|
|
|
|
|
|
|
|
|
|
|
|
Ankle fracture
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Avulsion fracture
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Fracture
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Thermal burn
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Wrist fracture
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Cardiac disorders
|
|
|
|
|
|
|
|
|
|
|
|
|
Atrioventricular block first degree
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
Bradycardia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
Mitral valve thickening
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Sinus bradycardia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Tachycardia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
2 |
0 |
1 |
0 |
0 |
3 |
Ventricular arrhythmia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Nervous system disorders
|
|
|
|
|
|
|
|
|
|
|
|
|
Ataxia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Balance disorder
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Dizziness
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
2 / 7 (28.57%) |
0 / 6 (0.00%) |
2 / 5 (40.00%) |
1 / 12 (8.33%) |
2 / 12 (16.67%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
1 / 10 (10.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
11 / 95 (11.58%) |
occurrences all number
|
1 |
3 |
0 |
2 |
1 |
2 |
0 |
2 |
1 |
1 |
0 |
13 |
Dysgeusia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
1 / 5 (20.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
2 / 10 (20.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
7 / 95 (7.37%) |
occurrences all number
|
0 |
0 |
2 |
1 |
1 |
0 |
2 |
0 |
2 |
0 |
1 |
9 |
Headache
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
1 / 5 (20.00%) |
2 / 12 (16.67%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
5 / 95 (5.26%) |
occurrences all number
|
0 |
0 |
0 |
2 |
2 |
1 |
0 |
0 |
0 |
1 |
0 |
6 |
Hyperaesthesia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
2 |
Hypoaesthesia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
0 |
0 |
4 |
Neuropathy peripheral
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
3 / 12 (25.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
4 / 95 (4.21%) |
occurrences all number
|
0 |
0 |
0 |
0 |
3 |
3 |
0 |
0 |
0 |
0 |
0 |
6 |
Paraesthesia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
2 |
Peripheral sensory neuropathy
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
3 / 95 (3.16%) |
occurrences all number
|
0 |
1 |
2 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
4 |
Seizure
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
1 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
Somnolence
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Syncope
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
0 |
0 |
2 |
Taste disorder
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
Tongue paralysis
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Transient ischaemic attack
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Blood and lymphatic system disorders
|
|
|
|
|
|
|
|
|
|
|
|
|
Anaemia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 5 (60.00%) |
2 / 7 (28.57%) |
3 / 6 (50.00%) |
2 / 5 (40.00%) |
8 / 12 (66.67%) |
7 / 12 (58.33%) |
3 / 10 (30.00%) |
5 / 9 (55.56%) |
3 / 10 (30.00%) |
2 / 10 (20.00%) |
2 / 9 (22.22%) |
40 / 95 (42.11%) |
occurrences all number
|
4 |
3 |
3 |
3 |
9 |
9 |
3 |
8 |
3 |
4 |
3 |
52 |
Leukopenia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
1 / 9 (11.11%) |
1 / 10 (10.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
5 / 95 (5.26%) |
occurrences all number
|
1 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
3 |
0 |
7 |
Lymphopenia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
0 |
2 |
Neutropenia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
3 / 12 (25.00%) |
1 / 12 (8.33%) |
1 / 10 (10.00%) |
2 / 9 (22.22%) |
3 / 10 (30.00%) |
2 / 10 (20.00%) |
1 / 9 (11.11%) |
14 / 95 (14.74%) |
occurrences all number
|
0 |
1 |
0 |
0 |
5 |
2 |
1 |
3 |
6 |
2 |
1 |
21 |
Thrombocytopenia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
2 / 12 (16.67%) |
0 / 12 (0.00%) |
2 / 10 (20.00%) |
3 / 9 (33.33%) |
4 / 10 (40.00%) |
1 / 10 (10.00%) |
2 / 9 (22.22%) |
15 / 95 (15.79%) |
occurrences all number
|
2 |
0 |
0 |
0 |
2 |
0 |
2 |
4 |
7 |
1 |
2 |
20 |
Ear and labyrinth disorders
|
|
|
|
|
|
|
|
|
|
|
|
|
Ear congestion
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
1 / 5 (20.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Tinnitus
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Vertigo
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Eye disorders
|
|
|
|
|
|
|
|
|
|
|
|
|
Chorioretinopathy
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Dry eye
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
3 / 95 (3.16%) |
occurrences all number
|
0 |
1 |
0 |
0 |
1 |
0 |
0 |
1 |
0 |
0 |
0 |
3 |
Eye irritation
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
Eye pain
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Eye swelling
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Periorbital oedema
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Retinal detachment
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
Retinal disorder
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
0 |
0 |
2 |
Retinal exudates
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Subretinal fluid
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Vision blurred
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
2 / 7 (28.57%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
3 / 95 (3.16%) |
occurrences all number
|
0 |
2 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
3 |
Visual impairment
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
2 |
Vitreous floaters
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
2 |
Gastrointestinal disorders
|
|
|
|
|
|
|
|
|
|
|
|
|
Abdominal discomfort
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
1 / 5 (20.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
3 / 95 (3.16%) |
occurrences all number
|
0 |
0 |
0 |
1 |
0 |
0 |
1 |
2 |
0 |
0 |
0 |
4 |
Abdominal distension
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
1 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
Abdominal pain
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
3 / 7 (42.86%) |
0 / 6 (0.00%) |
1 / 5 (20.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
1 / 10 (10.00%) |
3 / 9 (33.33%) |
0 / 10 (0.00%) |
1 / 10 (10.00%) |
2 / 9 (22.22%) |
13 / 95 (13.68%) |
occurrences all number
|
1 |
3 |
0 |
1 |
0 |
1 |
1 |
4 |
0 |
2 |
2 |
15 |
Abdominal pain lower
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Abdominal pain upper
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
3 / 95 (3.16%) |
occurrences all number
|
1 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
3 |
Anal incontinence
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
Aphthous ulcer
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Ascites
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Constipation
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
2 / 6 (33.33%) |
2 / 5 (40.00%) |
1 / 12 (8.33%) |
2 / 12 (16.67%) |
3 / 10 (30.00%) |
2 / 9 (22.22%) |
0 / 10 (0.00%) |
2 / 10 (20.00%) |
2 / 9 (22.22%) |
17 / 95 (17.89%) |
occurrences all number
|
0 |
2 |
2 |
2 |
1 |
2 |
3 |
2 |
0 |
2 |
2 |
18 |
Diarrhoea
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
3 / 5 (60.00%) |
5 / 7 (71.43%) |
2 / 6 (33.33%) |
3 / 5 (60.00%) |
6 / 12 (50.00%) |
7 / 12 (58.33%) |
4 / 10 (40.00%) |
5 / 9 (55.56%) |
9 / 10 (90.00%) |
1 / 10 (10.00%) |
5 / 9 (55.56%) |
50 / 95 (52.63%) |
occurrences all number
|
3 |
12 |
6 |
3 |
6 |
10 |
6 |
6 |
13 |
1 |
6 |
72 |
Dry mouth
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
2 / 12 (16.67%) |
0 / 12 (0.00%) |
3 / 10 (30.00%) |
2 / 9 (22.22%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
10 / 95 (10.53%) |
occurrences all number
|
1 |
0 |
1 |
0 |
2 |
0 |
3 |
3 |
1 |
0 |
0 |
11 |
Duodenal ulcer
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Dyspepsia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
1 / 10 (10.00%) |
1 / 9 (11.11%) |
4 / 95 (4.21%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
1 |
0 |
1 |
0 |
1 |
2 |
5 |
Dysphagia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Flatulence
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
2 |
Gastrooesophageal reflux disease
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
4 / 95 (4.21%) |
occurrences all number
|
0 |
0 |
1 |
0 |
0 |
0 |
1 |
1 |
0 |
0 |
1 |
4 |
Haemorrhoids
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
Intra-abdominal haematoma
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Lip dry
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Lip pain
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Lip swelling
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
2 |
Mouth ulceration
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
Nausea
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
3 / 7 (42.86%) |
4 / 6 (66.67%) |
3 / 5 (60.00%) |
7 / 12 (58.33%) |
7 / 12 (58.33%) |
3 / 10 (30.00%) |
3 / 9 (33.33%) |
5 / 10 (50.00%) |
4 / 10 (40.00%) |
5 / 9 (55.56%) |
44 / 95 (46.32%) |
occurrences all number
|
0 |
6 |
5 |
3 |
10 |
8 |
4 |
5 |
6 |
5 |
6 |
58 |
Oesophageal discomfort
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
1 / 5 (20.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Oesophagitis
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
2 |
Oral discomfort
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Proctalgia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
Rectal haemorrhage
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
1 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
2 |
Retching
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
1 / 5 (20.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Stomatitis
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
2 / 7 (28.57%) |
3 / 6 (50.00%) |
2 / 5 (40.00%) |
8 / 12 (66.67%) |
3 / 12 (25.00%) |
3 / 10 (30.00%) |
5 / 9 (55.56%) |
6 / 10 (60.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
33 / 95 (34.74%) |
occurrences all number
|
0 |
2 |
6 |
2 |
12 |
3 |
3 |
7 |
6 |
1 |
0 |
42 |
Tongue discolouration
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Tooth loss
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Toothache
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
Upper gastrointestinal haemorrhage
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Vomiting
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 5 (40.00%) |
5 / 7 (71.43%) |
3 / 6 (50.00%) |
1 / 5 (20.00%) |
3 / 12 (25.00%) |
5 / 12 (41.67%) |
3 / 10 (30.00%) |
5 / 9 (55.56%) |
2 / 10 (20.00%) |
3 / 10 (30.00%) |
6 / 9 (66.67%) |
38 / 95 (40.00%) |
occurrences all number
|
2 |
6 |
7 |
1 |
10 |
5 |
3 |
8 |
2 |
3 |
8 |
55 |
Hepatobiliary disorders
|
|
|
|
|
|
|
|
|
|
|
|
|
Gallbladder obstruction
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Hepatosplenomegaly
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Skin and subcutaneous tissue disorders
|
|
|
|
|
|
|
|
|
|
|
|
|
Alopecia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
2 / 12 (16.67%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
2 / 9 (22.22%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
6 / 95 (6.32%) |
occurrences all number
|
0 |
1 |
1 |
0 |
3 |
0 |
0 |
2 |
0 |
0 |
0 |
7 |
Dermatitis acneiform
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
2 / 5 (40.00%) |
3 / 7 (42.86%) |
3 / 6 (50.00%) |
1 / 5 (20.00%) |
4 / 12 (33.33%) |
2 / 12 (16.67%) |
3 / 10 (30.00%) |
1 / 9 (11.11%) |
2 / 10 (20.00%) |
2 / 10 (20.00%) |
5 / 9 (55.56%) |
28 / 95 (29.47%) |
occurrences all number
|
2 |
13 |
4 |
1 |
4 |
2 |
4 |
1 |
2 |
2 |
5 |
40 |
Dry skin
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
1 / 7 (14.29%) |
2 / 6 (33.33%) |
0 / 5 (0.00%) |
2 / 12 (16.67%) |
4 / 12 (33.33%) |
3 / 10 (30.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
1 / 10 (10.00%) |
1 / 9 (11.11%) |
16 / 95 (16.84%) |
occurrences all number
|
1 |
1 |
2 |
0 |
2 |
4 |
3 |
1 |
0 |
1 |
1 |
16 |
Eczema asteatotic
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Erythema
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
1 / 5 (20.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
4 / 95 (4.21%) |
occurrences all number
|
0 |
0 |
0 |
1 |
1 |
0 |
0 |
1 |
0 |
0 |
1 |
4 |
Hyperhidrosis
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
3 / 95 (3.16%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
0 |
3 |
Ingrowing nail
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Night sweats
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
1 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
Pain of skin
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Palmar-plantar erythrodysaesthesia syndrome
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Photosensitivity reaction
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
1 / 5 (20.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
3 / 95 (3.16%) |
occurrences all number
|
0 |
0 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
3 |
Pruritus
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
2 / 12 (16.67%) |
1 / 12 (8.33%) |
4 / 10 (40.00%) |
2 / 9 (22.22%) |
2 / 10 (20.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
11 / 95 (11.58%) |
occurrences all number
|
0 |
0 |
0 |
0 |
4 |
1 |
4 |
2 |
2 |
0 |
0 |
13 |
Rash
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
3 / 7 (42.86%) |
3 / 6 (50.00%) |
1 / 5 (20.00%) |
8 / 12 (66.67%) |
8 / 12 (66.67%) |
4 / 10 (40.00%) |
5 / 9 (55.56%) |
7 / 10 (70.00%) |
5 / 10 (50.00%) |
1 / 9 (11.11%) |
45 / 95 (47.37%) |
occurrences all number
|
0 |
3 |
7 |
2 |
16 |
10 |
6 |
13 |
8 |
5 |
1 |
71 |
Rash macular
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
2 |
1 |
0 |
0 |
0 |
3 |
Rash maculo-papular
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
2 / 10 (20.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
6 / 95 (6.32%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
1 |
2 |
0 |
1 |
1 |
0 |
6 |
Rash pruritic
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Skin burning sensation
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
1 / 5 (20.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
Skin fissures
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
4 / 95 (4.21%) |
occurrences all number
|
0 |
1 |
0 |
0 |
1 |
1 |
0 |
0 |
1 |
0 |
0 |
4 |
Skin necrosis
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
1 |
Urticaria
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
2 |
Renal and urinary disorders
|
|
|
|
|
|
|
|
|
|
|
|
|
Acute kidney injury
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
1 |
0 |
1 |
0 |
0 |
0 |
2 |
Chronic kidney disease
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
1 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
2 |
Dysuria
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
2 |
Haematuria
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
1 / 5 (20.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
4 / 95 (4.21%) |
occurrences all number
|
0 |
0 |
0 |
1 |
0 |
1 |
0 |
0 |
1 |
0 |
1 |
4 |
Hydronephrosis
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
Micturition urgency
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Proteinuria
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
4 / 12 (33.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
7 / 95 (7.37%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
4 |
0 |
0 |
2 |
1 |
0 |
8 |
Renal failure
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Urinary incontinence
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
1 / 5 (20.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Urinary retention
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Musculoskeletal and connective tissue disorders
|
|
|
|
|
|
|
|
|
|
|
|
|
Arthralgia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Arthritis
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Back pain
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
1 / 10 (10.00%) |
2 / 9 (22.22%) |
6 / 95 (6.32%) |
occurrences all number
|
0 |
0 |
1 |
0 |
1 |
0 |
1 |
0 |
0 |
1 |
3 |
7 |
Flank pain
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
1 |
Groin pain
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
Muscle spasms
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
0 |
0 |
2 |
Muscle swelling
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Muscle tightness
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Muscular weakness
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Musculoskeletal pain
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
1 / 5 (20.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
1 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
2 |
Musculoskeletal stiffness
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
Myalgia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
4 / 95 (4.21%) |
occurrences all number
|
0 |
1 |
1 |
0 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
4 |
Myositis
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
1 / 5 (20.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Neck pain
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
2 |
Pain in extremity
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
1 / 5 (20.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
2 |
Infections and infestations
|
|
|
|
|
|
|
|
|
|
|
|
|
Arthritis infective
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Bronchitis
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Catheter site cellulitis
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Cellulitis
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
0 |
0 |
2 |
Erysipelas
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
2 |
Eye infection
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Fungal infection
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
1 |
0 |
1 |
0 |
0 |
0 |
2 |
Herpes simplex
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
Localised infection
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
2 |
Paronychia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Pneumonia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Postoperative wound infection
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Pustule
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Rash pustular
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
1 |
2 |
Rhinitis
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
Skin infection
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Staphylococcal skin infection
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Tinea cruris
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Tooth infection
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
Upper respiratory tract infection
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
1 |
0 |
0 |
4 |
Urinary tract infection
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
1 / 5 (20.00%) |
1 / 12 (8.33%) |
0 / 12 (0.00%) |
1 / 10 (10.00%) |
1 / 9 (11.11%) |
1 / 10 (10.00%) |
1 / 10 (10.00%) |
1 / 9 (11.11%) |
8 / 95 (8.42%) |
occurrences all number
|
1 |
0 |
0 |
1 |
1 |
0 |
1 |
1 |
1 |
1 |
1 |
8 |
Viral infection
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
Vulvovaginal mycotic infection
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Metabolism and nutrition disorders
|
|
|
|
|
|
|
|
|
|
|
|
|
Appetite disorder
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
Decreased appetite
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
2 / 7 (28.57%) |
0 / 6 (0.00%) |
2 / 5 (40.00%) |
3 / 12 (25.00%) |
3 / 12 (25.00%) |
1 / 10 (10.00%) |
2 / 9 (22.22%) |
1 / 10 (10.00%) |
3 / 10 (30.00%) |
4 / 9 (44.44%) |
21 / 95 (22.11%) |
occurrences all number
|
0 |
2 |
0 |
2 |
4 |
3 |
1 |
2 |
1 |
3 |
4 |
22 |
Dehydration
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
2 / 12 (16.67%) |
0 / 10 (0.00%) |
2 / 9 (22.22%) |
2 / 10 (20.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
9 / 95 (9.47%) |
occurrences all number
|
0 |
0 |
1 |
0 |
1 |
2 |
0 |
2 |
3 |
0 |
2 |
11 |
Hypercalcaemia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
1 |
Hyperglycaemia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
1 / 12 (8.33%) |
2 / 10 (20.00%) |
0 / 9 (0.00%) |
2 / 10 (20.00%) |
1 / 10 (10.00%) |
0 / 9 (0.00%) |
6 / 95 (6.32%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
1 |
3 |
0 |
2 |
1 |
0 |
7 |
Hyperkalaemia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
Hypernatraemia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
2 / 95 (2.11%) |
occurrences all number
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
0 |
1 |
3 |
Hyperphosphataemia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
1 / 5 (20.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Hypertriglyceridaemia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Hypoalbuminaemia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
1 / 5 (20.00%) |
2 / 7 (28.57%) |
0 / 6 (0.00%) |
1 / 5 (20.00%) |
3 / 12 (25.00%) |
4 / 12 (33.33%) |
2 / 10 (20.00%) |
4 / 9 (44.44%) |
4 / 10 (40.00%) |
1 / 10 (10.00%) |
1 / 9 (11.11%) |
23 / 95 (24.21%) |
occurrences all number
|
1 |
2 |
0 |
1 |
4 |
4 |
2 |
5 |
4 |
1 |
1 |
25 |
Hypocalcaemia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
1 / 12 (8.33%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
2 / 10 (20.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
5 / 95 (5.26%) |
occurrences all number
|
0 |
0 |
0 |
0 |
1 |
1 |
0 |
1 |
2 |
0 |
0 |
5 |
Hypoglycaemia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Hypokalaemia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
0 / 5 (0.00%) |
2 / 12 (16.67%) |
2 / 12 (16.67%) |
2 / 10 (20.00%) |
2 / 9 (22.22%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
2 / 9 (22.22%) |
12 / 95 (12.63%) |
occurrences all number
|
0 |
0 |
1 |
0 |
2 |
2 |
2 |
2 |
1 |
0 |
3 |
13 |
Hypomagnesaemia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
1 / 6 (16.67%) |
1 / 5 (20.00%) |
4 / 12 (33.33%) |
2 / 12 (16.67%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
11 / 95 (11.58%) |
occurrences all number
|
0 |
0 |
1 |
1 |
6 |
3 |
0 |
2 |
1 |
0 |
2 |
16 |
Hyponatraemia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
0 / 7 (0.00%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
2 / 12 (16.67%) |
1 / 12 (8.33%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 10 (10.00%) |
0 / 10 (0.00%) |
1 / 9 (11.11%) |
5 / 95 (5.26%) |
occurrences all number
|
0 |
0 |
0 |
0 |
4 |
1 |
0 |
0 |
1 |
0 |
1 |
7 |
Hypophosphataemia
|
|
|
|
|
|
|
|
|
|
|
|
|
subjects affected / exposed
|
0 / 5 (0.00%) |
1 / 7 (14.29%) |
0 / 6 (0.00%) |
0 / 5 (0.00%) |
0 / 12 (0.00%) |
0 / 12 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
0 / 10 (0.00%) |
0 / 10 (0.00%) |
0 / 9 (0.00%) |
1 / 95 (1.05%) |
occurrences all number
|
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |